UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 109

Sortiert nach

Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development

mAbs, 2016-02, Vol.8 (2), p.229-245

2016

Volltextzugriff (PDF)

Brain Disposition of Antibody-Based Therapeutics: Dogma, Approaches and Perspectives

International journal of molecular sciences, 2021-06, Vol.22 (12), p.6442

2021

Volltextzugriff (PDF)

Advances in Immuno-PET for the Detection of Cancer and Assessment of Response to Therapy

Current medicinal chemistry, 2021-01, Vol.28 (4), p.647

2021

Volltextzugriff (PDF)

Effects of Charge on Antibody Tissue Distribution and Pharmacokinetics

Bioconjugate chemistry, 2010-12, Vol.21 (12), p.2153-2163

2010

Volltextzugriff (PDF)

Physiochemical and Biochemical Factors Influencing the Pharmacokinetics of Antibody Therapeutics

The AAPS journal, 2012-09, Vol.14 (3), p.554-558

2012

Volltextzugriff (PDF)

Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats

mAbs, 2010-11, Vol.2 (6), p.613-624

2010

Volltextzugriff (PDF)

Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics

The Journal of biological chemistry, 2015-12, Vol.290 (50), p.29732-29741

2015

Volltextzugriff (PDF)

Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody–Drug Conjugates in Rats

Bioconjugate chemistry, 2011-10, Vol.22 (10), p.1994-2004

2011

Volltextzugriff (PDF)

Spatio-temporal biodistribution of 89Zr-oxine labeled huLym-1-A-BB3z-CAR T-cells by PET imaging in a preclinical tumor model

Scientific reports, 2021-07, Vol.11 (1), p.1-13, Article 15077

2021

Volltextzugriff (PDF)

Posttranslational Modifications and the Immunogenicity of Biotherapeutics

Journal of Immunology Research, 2016-01, Vol.2016, p.5358272-15

2016

Volltextzugriff (PDF)

Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins

Journal of Immunology Research, 2016-01, Vol.2016, p.2342187-9

2016

Volltextzugriff (PDF)

Biodistribution and efficacy of an anti-TENB2 antibody-drug conjugate in a patient-derived model of prostate cancer

Oncotarget, 2019-10, Vol.10 (58), p.6234-6244

2019

Volltextzugriff (PDF)

Lym-1 Chimeric Antigen Receptor T Cells Exhibit Potent Anti-Tumor Effects against B-Cell Lymphoma

International journal of molecular sciences, 2017-12, Vol.18 (12), p.2773

2017

Volltextzugriff (PDF)

Recent Advances in Assessing Immunogenicity of Therapeutic Proteins: Impact on Biotherapeutic Development

Journal of Immunology Research, 2016-01, Vol.2016, p.8141269-2

2016

Volltextzugriff (PDF)

Principles of N-Linked Glycosylation Variations of IgG-Based Therapeutics: Pharmacokinetic and Functional Considerations

Antibodies (Basel), 2020-06, Vol.9 (2), p.22

2020

Volltextzugriff (PDF)

An integrated approach to identify normal tissue expression of targets for antibody‐drug conjugates: case study of TENB2

British journal of pharmacology, 2013-01, Vol.168 (2), p.445-457

2013

Volltextzugriff (PDF)

Effects of anti-VEGF on predicted antibody biodistribution: roles of vascular volume, interstitial volume, and blood flow

PloS one, 2011-03, Vol.6 (3), p.e17874

2011

Volltextzugriff (PDF)

Generation of Rituximab Polymer May Cause Hyper-Cross-linking–Induced Apoptosis in Non-Hodgkin's Lymphomas

Clinical cancer research, 2005-08, Vol.11 (16), p.5971-5980

2005

Volltextzugriff (PDF)

A Humanized Lym-1 CAR with Novel DAP10/DAP12 Signaling Domains Demonstrates Reduced Tonic Signaling and Increased Antitumor Activity in B-Cell Lymphoma Models

Clinical cancer research, 2020-07, Vol.26 (14), p.3694-3706

2020

Volltextzugriff (PDF)

Pivotal Study of Iodine-131–Labeled Chimeric Tumor Necrosis Treatment Radioimmunotherapy in Patients With Advanced Lung Cancer

Journal of clinical oncology, 2005-03, Vol.23 (7), p.1538-1547

2005

Volltextzugriff (PDF)

Drug Delivery across the Blood–Brain Barrier

Molecular pharmaceutics, 2013-05, Vol.10 (5), p.1471-1472

2013

Volltextzugriff (PDF)

Enhancing brain entry and therapeutic activity of chimeric antigen receptor T cells with intra-arterial NEO100 in a mouse model of CNS lymphoma

Journal of neurosurgery, 2024-06, Vol.140 (6), p.1549

2024

Volltextzugriff (PDF)

Targeted and Untargeted CD137L Fusion Proteins for the Immunotherapy of Experimental Solid Tumors

Clinical cancer research, 2007-05, Vol.13 (9), p.2758-2767

2007

Volltextzugriff (PDF)

1 – 25 von 109

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(88)
Mit Volltextzugriff
(96)

Publikationsform

Sprache

Englisch
(109)
Japanisch
(19)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development

Brain Disposition of Antibody-Based Therapeutics: Dogma, Approaches and Perspectives

Advances in Immuno-PET for the Detection of Cancer and Assessment of Response to Therapy

Effects of Charge on Antibody Tissue Distribution and Pharmacokinetics

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates

Physiochemical and Biochemical Factors Influencing the Pharmacokinetics of Antibody Therapeutics

Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats

Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics

Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody–Drug Conjugates in Rats

Spatio-temporal biodistribution of 89Zr-oxine labeled huLym-1-A-BB3z-CAR T-cells by PET imaging in a preclinical tumor model

Posttranslational Modifications and the Immunogenicity of Biotherapeutics

Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins

Biodistribution and efficacy of an anti-TENB2 antibody-drug conjugate in a patient-derived model of prostate cancer

Lym-1 Chimeric Antigen Receptor T Cells Exhibit Potent Anti-Tumor Effects against B-Cell Lymphoma

Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration

Recent Advances in Assessing Immunogenicity of Therapeutic Proteins: Impact on Biotherapeutic Development

Principles of N-Linked Glycosylation Variations of IgG-Based Therapeutics: Pharmacokinetic and Functional Considerations

An integrated approach to identify normal tissue expression of targets for antibody‐drug conjugates: case study of TENB2

Effects of anti-VEGF on predicted antibody biodistribution: roles of vascular volume, interstitial volume, and blood flow

Generation of Rituximab Polymer May Cause Hyper-Cross-linking–Induced Apoptosis in Non-Hodgkin's Lymphomas

A Humanized Lym-1 CAR with Novel DAP10/DAP12 Signaling Domains Demonstrates Reduced Tonic Signaling and Increased Antitumor Activity in B-Cell Lymphoma Models

Pivotal Study of Iodine-131–Labeled Chimeric Tumor Necrosis Treatment Radioimmunotherapy in Patients With Advanced Lung Cancer

Drug Delivery across the Blood–Brain Barrier

Enhancing brain entry and therapeutic activity of chimeric antigen receptor T cells with intra-arterial NEO100 in a mouse model of CNS lymphoma

Targeted and Untargeted CD137L Fusion Proteins for the Immunotherapy of Experimental Solid Tumors

Suchergebnisse filtern